Detecting KRAS mutations in pancreatic cystic neoplasms: droplet digital PCR versus targeted next-generation sequencing

DNA-based testing of pancreatic cyst fluid (PCF), obtained by endoscopic ultrasound fine needle aspiration (EUS-FNA) may improve diagnostic accuracy for differentiation between types of pancreatic cystic neoplasms (PCN),1 which is currently suboptimal. Mutations in DNA (a.o. KRAS, GNAS) can differentiate non-mucinous from (pre)-malignant, mucinous PCN. Various techniques are available to detect mutations in DNA; including targeted next generation sequencing (NGS), like Ion Torrent NGS, and since more recently droplet digital PCR (ddPCR).